Lv1
20 积分 2021-06-08 加入
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
4天前
已完结
Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study
16天前
已完结
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer
16天前
已完结
Cyclin-dependent kinase 4/6 inhibitors as neoadjuvant therapy of hormone receptor-positive/HER2-negative early breast cancer: What do we know so far?
16天前
已完结
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
16天前
已完结
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial
17天前
已完结
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
19天前
已完结
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
19天前
已完结
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
23天前
已完结
Targeting brain metastases in breast cancer
24天前
已完结
皖公网安备34019202002308
